Bringing the Oncology Community Together

Dr. Beer on the Implications of the PREVAIL Study

Tomasz Beer, MD, FACP
Published Online: Monday, February 3, 2014
Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.

Beer says that is a wonderful time to contemplate how two effective drugs could both be used for patients in this space. As the PREVAIL study was not designed to compare abiraterone and enzalutamide, it cannot be said that one drug is superior or inferior.

A decision to treat with abiraterone or enzalutamide must be made on a physician-by-physician and patient-by-patient basis as there are specific considerations to be made. For example, Beer notes, enzalutamide does not require steroids, so for patients for whom giving steroids is a concern, enzalutamide may be preferred.

Beer says that there are many differences in the two studies and the data that may help a physician make decisions.

<<< View more from the 2014 GU Cancers Symposium

Related Articles
Early Detection of Metastatic Prostate Cancer
In this segment, panelists discuss advanced imaging techniques that can be used to detect metastases earlier for patients with castration-resistant prostate cancer.
Adding ADT to RT Reduces Risk of Progression in Localized Prostate Cancer
Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.
Pretreatment Genetic Test Predicts Recurrence in Prostate Cancer
A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.